All In Biotech

Drug Trial Radar · NCT04492033

A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients

A Phase 1b/2a Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Patients With Advanced or Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jan 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

41

Actual

Start

Jun 22, 2020

Primary completion

Jan 8, 2024

Study completion Jan 9, 2025

Sponsor

Lead sponsor
Handok Inc.Industry
Sponsor type
Industry
Collaborators
Compass Therapeutics; ABL Bio, Inc.
First posted
Jul 30, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a Phase 1b/2 multi-center study to assess the safety, tolerability, pharmacokinetics of CTX-009 (ABL001) in combination with Irinotecan or Paclitaxel in patients with advanced or metastatic solid tumors.

Conditions

  • P1b: Advanced Solid Tumors
  • P2: Biliary Tract Cancer

Interventions

  • CTX-009 (ABL001)Drug

    CTX-009 (ABL001) will be administered biweekly.

  • PaclitaxelDrug

    Paclitaxel will be administered weekly.

  • IrinotecanDrug

    Irinotecan will be administered biweekly.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. P1b: Proportion of subjects with Dose-Limiting Toxicity (DLT)Time frame: From Day 1 until disease progression or Day 28, whichever came first
  2. P2: Objective response rate (ORR) of CTX-009 (ABL001) in combination with paclitaxel in patients with BTCTime frame: Up to approximately 24 months

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Seoul National University Bundang Hospital

    Seongnam-si, South Korea

  • Asan Medical Center

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.